Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Spotlight On Financing


Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Public Company Edition: Upstream grossed $255m and CAMP4 raised $75m in October’s first initial public offerings. In follow-on offerings, Crinetics and Scholar Rock brought in $500m and $300m, respectively. Also, Turnstone cut 60% of its workforce and Gritstone filed for bankruptcy.

Focus On Asia


Data


R&D


MeiraGTx’s Phase II Gene Therapy For Parkinson’s Shows Efficacy, Safety

MeiraGTx’s Phase II Gene Therapy For Parkinson’s Shows Efficacy, Safety

 
• By 

Although the data are from a small bridging study, MeiraGTx plans to discuss Phase III options for AAV-GAD in Parkinson’s disease after showing efficacy on a disease rating scale and a quality-of-life measure.

Lilly Hopes To Differentiate Omvoh In Crohn’s With Histologic Data

Lilly Hopes To Differentiate Omvoh In Crohn’s With Histologic Data

 
• By 

The IL-23 antagonist Omvoh is under FDA/EMA review for Crohn’s disease; Lilly reported new Phase III data showing the drug is better than Stelara on multiple endpoints of histologic response.

Business


Financing Is Improving, But Cell And Gene Therapy Firms May Be Last To Feel It

Financing Is Improving, But Cell And Gene Therapy Firms May Be Last To Feel It

 
• By 

ARM’s Cell and Gene Meeting on the Mesa offered optimism that a biopharma financial market recovery is under way, but cell and gene therapies still are seen as risky investments.

As Stelara Sunset Begins, J&J Says Tremfya Will Step Up

As Stelara Sunset Begins, J&J Says Tremfya Will Step Up

 

Sales of Johnson & Johnson’s Stelara declined 6.6% in the third quarter as the first biosimilars launched in Europe and US sales were softer than expected.

Seraxis Takes Its Islet Cell Tech Into The Clinic

Seraxis Takes Its Islet Cell Tech Into The Clinic

 

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

Lilly CEO Challenges ‘Small Market’ UK To Become More Attractive To Pharma

Lilly CEO Challenges ‘Small Market’ UK To Become More Attractive To Pharma

 
• By 

The US major is investing over $360m in new money into the UK but the country has being losing its lustre as an appealing place to invest since Brexit and needs to offer more to multinationals.

Scrip Originals


Stock Watch: Two Elephants In The Q3 Room

Stock Watch: Two Elephants In The Q3 Room

 
• By 

New product launches come with great expectations, which are sometimes unrealistic. This can lead to disappointment. Lately, market access restrictions are exacerbating sales challenges.

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

 
• By 

Public Company Edition: Upstream grossed $255m and CAMP4 raised $75m in October’s first initial public offerings. In follow-on offerings, Crinetics and Scholar Rock brought in $500m and $300m, respectively. Also, Turnstone cut 60% of its workforce and Gritstone filed for bankruptcy.

Pipeline Watch: Four Approvals And Five Phase III Readouts

Pipeline Watch: Four Approvals And Five Phase III Readouts

 
• By 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Spyre Therapeutics Secures Chief Medical Officer From Abivax

Executives On The Move: Spyre Therapeutics Secures Chief Medical Officer From Abivax

 
• By 

Recent moves in the industry include C-suite changes at Cybin, Biomarin and Nuvation Bio, plus Novita Pharmaceuticals gets a new chief executive officer.